Novartis AG ADR (NVS)vsPrivia Health Group Inc (PRVA)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $280.79B
PRVA
Privia Health Group Inc
$24.69
-0.60%
HEALTHCARE · Cap: $3.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 2570% more annual revenue ($56.67B vs $2.12B). NVS leads profitability with a 24.7% profit margin vs 1.1%. NVS trades at a lower P/E of 20.3x. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
PRVA
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.2%
Fair Value
$109.78
Current Price
$147.85
$38.07 premium
Margin of Safety
+70.2%
Fair Value
$72.49
Current Price
$24.69
$47.80 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 27.8%
Generating 1.6B in free cash flow
Earnings expanding 132.8% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
17.4% revenue growth
Areas to Watch
2.2% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Earnings declined 11.6%
ROE of 4.0% — below average capital efficiency
1.1% margin — thin
Operating margin of 2.1%
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.
Bull Case : PRVA
The strongest argument for PRVA centers on EPS Growth, Debt/Equity, Altman Z-Score. Revenue growth of 17.4% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.
Bear Case : PRVA
The primary concerns for PRVA are Return on Equity, Profit Margin, Operating Margin. A P/E of 137.2x leaves little room for execution misses. Thin 1.1% margins leave little buffer for downturns.
Key Dynamics to Monitor
NVS profiles as a value stock while PRVA is a growth play — different risk/reward profiles.
PRVA carries more volatility with a beta of 0.87 — expect wider price swings.
PRVA is growing revenue faster at 17.4% — sustainability is the question.
NVS generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 48/100), backed by strong 24.7% margins. PRVA offers better value entry with a 70.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Privia Health Group Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Privia Health Group, Inc. is a population health technology and medical practice management company in the United States.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?